Arrowhead PharmaceuticalsNASDAQ: ARWR

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on October 11, 2024, the Company's Board of Directors approved “inducement” grants to 34 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 66,750 restricted stock units. The grants are outside the Company's stockholder-approved equity incentive plans and ve.

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-INHBE, the company's investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity. Arrowhead also plans to file for regulatory clearance before the end of 2024 to initiate a clinical trial for its second obesity candidate, ARO-ALK7. “Arrowhead's two investigational R.

Shares of Arrowhead Pharmaceuticals (ARWR) gained Tuesday after the biotech firm announced positive results in a late-stage study of its experimental treatment for a rare metabolic disorder, and said it plans to request regulatory approval to market it.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) 2024 Summer Series R&D Webinar: Obesity/Metabolic - ARO-INHBE Conference August 14, 2024 2:00 PM ET Company Participants Vincent Anzalone - Vice President and Head of Investor Relations Dr. Carel Le Roux - Chair of Metabolic Medicine, University College Dublin Erik Bush - Senior Vice President, Biology Tao Pei - Senior Vice President, Discovery Chemistry James Hamilton - SVP, Discovery and Translational Medicine Operator Good afternoon, and welcome to the Arrowhead Summer Series of R&D Webinars Part 4. As a reminder, all participants are in a listen-only mode.

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced plans to advance investigational plozasiran into a Phase 3 cardiovascular outcomes trial called CAPITAN. This comes after promising results were recently announced from multiple clinical trials in three distinct patient populations, including the pivotal Phase 3 PALISADE study in patients with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome (FCS), the Phase 2 SHASTA-.

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that preclinical data on ARO-INHBE, an investigational RNAi-based medicine for the treatment of obesity and metabolic diseases, were presented at the American Diabetes Association (ADA) 84th Scientific Sessions, which were held June 21-24, in Orlando, FL, and virtually. The preclinical results demonstrate that ARO-INHBE substantially silenced hepatic expression of the INHBE gene, which has been ide.

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from the pivotal Phase 3 PALISADE study of investigational plozasiran in patients with genetically confirmed or clinically diagnosed familial chylomicronemia syndrome (FCS), a severe genetic disease with significant unmet need and no FDA approved therapies. PALISADE successfully met the primary endpoint of lowering triglycerides and met all key secondary endpoints, including reducin.

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 16th European Glaucoma Society (EGS) Congress – June 1-4, 2024 Title: Development and Characterization of Trabecular Meshwork Targeted RNAi Molecule Platform via Intracameral Administration for Glaucoma Date/Time: June 2, 2024, 10:30 a.m. IST Session: Poster Section Jefferies Global Healthcare Conference – June 5-6, 2024 Type: Fi.

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced results from the Phase 2b double blind, randomized ARCHES-2 study of investigational zodasiran (formerly ARO-ANG3) in patients with mixed hyperlipidemia. Zodasiran was associated with robust and durable reductions in triglycerides, triglyceride rich lipoprotein remnants, and total atherogenic lipoproteins, including LDL-C. These data were presented in a late-breaking oral presentation today at the.